PDCD1 and neoplasm: Although anti-PD-1 monotherapy resulted in robust antitumor efficacy in the MC38 tumor model, which is sensitive to anti-PD-1,63 combination therapy further improved the antitumor effect of anti-PD-1 treatment (Figure 1J).